Forest Hopes Efficacy In Blacks And Tolerability Will Set Bystolic Apart
Executive Summary
With approval of Forest/Mylan's Bystolic (nebivolol) - the newest member of a crowded beta blocker class - the company is gearing up to launch with an experienced sales force, data to differentiate the drug, and a price in line with one of the most commonly used drugs in the class
You may also be interested in...
Watson Seeks Partner For Rapaflo: Is There Still A Market For “Me-Too’s”?
Watson is in discussions with potential primary care partners for its newly approved benign prostatic hyperplasia therapy Rapaflo (silodosin)
Watson Seeks Partner For Rapaflo: Is There Still A Market For “Me-Too’s”?
Watson is in discussions with potential primary care partners for its newly approved benign prostatic hyperplasia therapy Rapaflo (silodosin)
Rapaflo Approved For BPH; Watson Will Stress Unique Selectivity
Even sponsors not aiming for the benign prostatic hyperplasia market should take notice of the Oct. 8 approval of Watson Pharmaceuticals' Rapaflo (silodosin)